AlvioLife®
Natural health product licensed in Canada
- Licence holder
- PLT Health Solutions Inc.
- NPN or DIN-HM
- 80088399
- Status
- Active licence
- Licence date
- 19 September 2018
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Boswellia serrata Source : Gum oleoresin Extract : Matériel brut sec Extraction ratio : 10:1 Dry plant equivalent : 500 mg Potency : 30 % 3-Acetyl-11-keto-beta-boswellic acid | 50 mg | Not calculated |
| Aegle marmelos Source : Fruit Extract : Matériel brut sec Extraction ratio : 4:1 Dry plant equivalent : 200 mg | 50 mg | Not calculated |
Non-medicinal ingredients
Not provided.
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19 years | 1 Capsule | 2 Tous les jours |
Uses authorised in Canada
AlvioLife® helps to support lower respiratory tract health. AlvioLife® helps to support lower respiratory tract health that includes the bronchial tubes and the lungs¿ health. Supports healthy lower respiratory system function. Clinically shown to support healthy lower respiratory system function.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity (e.g. allergy) has been known to occur; in which case, discontinue use. Some people may experience mild gastrointestinal effects such as diarrhea, abdominal pain/cramps and nausea.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Consult your health care practitioner if you have severe bronchial asthma, chronic bronchitis and/or emphysema, or you suffer from concurrent systemic diseases, with cardiopulmonary tuberculosis, pulmonary eosinophilia, bronchiectasis, cancer, cardiovascular disorders or breathlessness due to cardiovascular disorders, hepatic dysfunction, neurological disorders and diarrhoeal disorders, respiratory tract infection and other serious medical illnesses. Consult your health care practitioner if you have history of lung disease (i.e., COPD, sarcoidosis), history of diabetes mellitus, insulin secreting tumor, or symptomatic hypoglycemia, HIV or other known immunodeficiency or history of liver disease or abnormal liver function. If symptoms persist or worsen, or new symptoms develop, discontinue use and consult a health care practitioner.
Source
Official Health Canada record, licence 80088399
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.